Powering Global Access Through an Integrated Supply Chain Infrastructure

The cell and gene therapy revolution is global. With clinical trials being conducted in countries around the world and commercial therapies reaching new patient populations every year, the need for integrated, compliant, and scalable supply chain support has never been more urgent. Yet many life science companies are still navigating a disjointed landscape of regional supply chain providers, customs requirements, and inconsistent quality frameworks.

At Cryoport Systems, we believe that patient access is the next hurdle the industry will need to tackle. That’s why we’re building a global network designed not just to move materials, but to unify the advanced therapy supply chain. Through an expanding footprint of strategically located facilities, regulatory expertise and support, and integrated supply chain services, we are helping organizations bring breakthrough therapies to markets more efficiently and with reduced risk.

A Global Vision, now a Reality

Over the past several years, Cryoport Systems has made substantial investments to expand and integrate our worldwide capabilities. Our approach is grounded in the belief that global doesn’t have to mean fragmented. Instead, we’re building a unified infrastructure that offers local access, global consistency, and real-world responsiveness.

This vision is already becoming reality. Our network now includes IntegriCell™ cryopreservation services, BioServices and biostorage, regulatory support and advisory services, logistics and transportation, and the industry’s most stringent quality standards across North America, Europe, and Asia-Pacific. With each new facility, we increase our ability to deliver end-to-end services closer to where our clients operate, minimizing shipping distances, customs complexity, and time to patient.

Seamless Service Across Regions

One of the biggest barriers to globalization in advanced therapies is regulatory complexity. Each country has its own requirements for temperature control, chain of custody, documentation, and import/export approvals.  These can vary not only by geography but by commodity type, trial phase, and intended use.

Our global network is designed to eliminate these barriers. Our teams are staffed with regional experts in trade compliance, Qualified Person (QP) release, customs brokerage, and regulatory consulting. Whether a sponsor needs to move a leukopak from a clinic in Munich to a CDMO in North Carolina, or a commercial therapy from a manufacturer in the U.S. to a hospital in Belgium, Cryoport Systems has the infrastructure and expertise to make it happen.

All of our locations operate under harmonized operational and quality systems, enabling a consistent experience regardless of geography. We maintain complete visibility and control through our Cryoportal® logistics management system and apply our proprietary Chain of Compliance® to all shipments, ensuring that equipment performance, handling, and location data are tracked at every step.

Infrastructure Built to Scale

As the number of clinical trials and commercial programs continues to grow, so too does the need for scalable supply chain infrastructure. At Cryoport Systems, we are not only keeping pace, but we are also building ahead of demand, so your progress never hits a speed bump.

In addition to our established global network, we recently launched our Global Supply Chain Hub in Stevenage, U.K., strategically located within one of Europe’s leading bioscience clusters. This facility delivers temperature-controlled logistics, near real-time shipment monitoring, and local regulatory support to streamline Advanced Therapy Medicinal Product (ATMP) distribution across Europe. With the inherent complexity of cross-border shipments, our Stevenage hub enables U.K.-based developers to efficiently launch and scale clinical trials throughout the EU.

Recognizing that ATMP development demands more than just logistics, we have expanded our BioServices Centers in France to provide secure GMP biorepository storage, patient sample processing, and compliant packaging and labeling services. These capabilities support both clinical and commercial programs and are further enhanced by in-region Qualified Person (QP) services that enable streamlined scalability into the broader European market.

The viability of cell-based therapies depends heavily on consistent, high-quality cryopreservation of leukapheresis-derived starting material. Our new IntegriCell™ Cryopreservation Center in Villers-le-Bouillet, Belgium offers validated cryopreservation processes integrated seamlessly with our logistics network. This facility ensures the highest level of quality control and process standardization from the point of collection through final delivery.

In late 2025, we will expand our European operations even further with the opening of a new Global Supply Chain Center in Paris. This facility will enhance our capabilities to support ATMP developers at scale by delivering integrated logistics and distribution, biostorage, kit production,  and risk-mitigating solutions under a single roof.

Looking ahead to early 2026, we will consolidate our current logistics operations in Irvine, California into a new state-of-the-art Global Supply Chain Center in Santa Ana, California. This facility will support fully integrated, end-to-end supply chain support and risk mitigation, with the footprint to enable expanded BioServices and biostorage and additional services as the industry continues to mature.

Each of these investments represents more than added capacity. They reinforce our long-term commitment to delivering certainty in the temperature-controlled supply chain, supporting the full lifecycle of advanced therapies with the infrastructure needed to accelerate innovation without compromising quality or compliance.

Local Presence, Global Power

Having physical infrastructure in multiple countries is only part of the equation. What truly differentiates our global network is our ability to combine local responsiveness with global integration.

This means a sponsor working in Asia-Pacific can access the same Cryoport Systems standards, systems, and expertise as a partner in Europe or the U.S. It means CDMOs expanding internationally don’t need to vet a new vendor in every region, they can scale with one trusted partner who deeply understands their program and can ensure continuity across borders. And it means therapies can reach patients faster, with less risk, because the supply chain has already been built to flex and scale.

As regulations evolve and geopolitical conditions shift, our embedded local teams help clients adapt without compromising compliance or patient timelines. From navigating post-Brexit UK/EU requirements to facilitating U.S./Asia transport lanes, our teams bring the insight and relationships needed to ensure successful delivery.

Integrated Services for Global Advantage

The true value of our global footprint is realized when evaluated alongside our end-to-end supply chain management platform. Because we offer a full scope of services, including biostorage, cryopreservation, kit production, packaging, labeling, logistics, consulting, and quality under one roof (and across continents), clients benefit from a level of efficiency and coordination that a patchwork network of single-service providers simply can’t match.

Rather than managing a complex spiderweb of handoffs and hoping for alignment, organizations partnering with Cryoport Systems engage a single partner that connects supply chain needs upstream and downstream of manufacturing. And because our services are delivered through a unified platform with shared data and quality standards, the result is lower risk, greater visibility, and faster time to market.

Building a Global Supply Chain Without Gaps

Cryoport Systems is not done growing. As we expand and evolve ahead of where the market is going, we remain focused on what matters most: Enabling the Outcome™ for the innovative companies developing next-generation therapeutics and the patients who depend on them.

We will continue to invest in infrastructure that meets tomorrow’s needs, in technology that connects the temperature-controlled supply chain from end-to-end, and in people who bring deep experience and local insight to every challenge. The future of advanced therapies is borderless, and the supply chain must be as well. Cryoport Systems is delivering on that vision by building a connected, global infrastructure that simplifies complexity, reduces risk, and accelerates progress. Through our expanding network, our integrated platform, and our deep expertise, we are helping life sciences organizations deliver on the promise of personalized medicine, anywhere in the world.

Learn more at www.cryoport.com